Time-to-treatment discontinuation (TTD) and real-world progression-free survival (rwPFS) as endpoints for comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients
Doebele, RC Perez, L Trinh, H Martinec, M Martina, R Riehl, T Krebs, Matthew G Meropol, NJ Wong, WB Crane, G
Doebele, RC
Perez, L
Trinh, H
Martinec, M
Martina, R
Riehl, T
Krebs, Matthew G
Meropol, NJ
Wong, WB
Crane, G
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2019
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Doebele R, Perez L, Trinh H, Martinec M, Martina R, Riehl T, et al. Time-to-treatment discontinuation (TTD) and real-world progression-free survival (rwPFS) as endpoints for comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients. J Clin Oncol. 2019;37(15).